Piramal Pharma Limited has informed the Exchange regarding change in Registered Office of the company.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma reported FY2026 standalone revenue of Rs. 4,782 crore (down 9.5% from Rs. 5,286 crore), though standalone PAT improved slightly to Rs. 700 crore from Rs. 691 crore. However, consolidated performance showed a significant decline with revenue of Rs. 8,869 crore (down 3% from Rs. 9,151 crore) and a net loss of Rs. 326 crore compared to profit of Rs. 91 crore in FY2025. The board approved re-appointment of key executives including Ms. Nandini Piramal (Chairperson) and Mr. Peter DeYoung (CEO) for 3-year terms, both subject to shareholder approval. The registered office will shift within Kurla, Mumbai from April 30, 2026. Statutory auditors issued an unmodified (clean) opinion on the financial statements.
The sharp swing to consolidated net loss despite stable standalone performance raises concerns about subsidiary-level profitability and debt levels. Investors should monitor the company's path to returning to consolidated profitability, though the clean audit opinion provides assurance on financial reporting quality.